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Abstract
The Centers for Disease Control and Prevention developed a biomonitoring method to rapidly and 
accurately quantify chromium and cobalt in human whole blood by ICP-MS. Many metal-on-
metal hip implants which contain significant amounts of chromium and cobalt are susceptible to 
metal degradation. This method is used to gather population data about chromium and cobalt 
exposure of the U.S. population that does not include people that have metal-on-metal hip 
implants so that reference value can be established for a baseline level in blood. We evaluated 
parameters such as; helium gas flow rate, choice and composition of the diluent solution for 
sample preparation, and sample rinse time to determine the optimal conditions for analysis. The 
limits of detection for chromium and cobalt in blood were determined to be 0.41 and 0.06 μg/L, 
respectively. Method precision, accuracy, and recovery for this method were determined using 
quality control material created in-house and historical proficiency testing samples.
We conducted experiments to determine if quantitative changes in the method parameters affect 
the results obtained by changing four parameters while analyzing human whole blood spiked with 
National Institute of Standard and Technology traceable materials: the dilution factor used during 
sample preparation, sample rinse time, diluent composition, and kinetic energy discrimination gas 
flow rate. The results at the increased and decreased levels for each parameter were statistically 
compared to the results obtained at the optimized parameters. We assessed the degree of 
reproducibility obtained under a variety of conditions and evaluated the method's robustness by 
analyzing the same set of proficiency testing samples by different analysts, on different 
instruments, with different reagents, and on different days.
The short-term stability of chromium and cobalt in human blood samples stored at room 
temperature was monitored over a time period of 64 hours by diluting and analyzing samples at 
different time intervals. The stability of chromium and cobalt post-dilution was also evaluated over 
a period of 48 hours and at two storage temperatures (room temperature and refrigerated at 4°C). 
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The results obtained during the stability studies showed that chromium and cobalt are stable in 
human blood for a period of 64 hours.
Graphical Abstract
An ICP-MS method to measure total chromium and cobalt in whole blood is validated and 
described.
Introduction
Chromium (Cr) is a naturally occurring element whose nutritional bioavailability and 
toxicity depends on its oxidation state. Trivalent chromium is considered an essential 
nutrient, while hexavalent chromium is a human carcinogen and a commonly encountered 
occupational hazard for humans.1, 2 Cobalt (Co) is considered essential because it is part of 
the B12 vitamin which is important for human brain function, nervous center function, and 
cell metabolism.3, 4 While it is essential at certain lower levels, exposures to high levels of 
cobalt can affect the heart and/or lungs. Elevated exposures in animals have been shown to 
affect the liver and kidneys. Research performed by the International Agency for Research 
on Cancer, in which direct contact with cobalt occurred, led the Agency for Toxic 
Substances and Disease Registry (ATSDR) to list cobalt as a possible carcinogen to 
animals.3 Chromium and cobalt play important roles clinically in cases where metal-on-
metal (MoM) hip implants fail and release these metals into the bloodstream. It is not known 
if the health effects of these two metals seen in animals will also be seen in humans. This 
uncertainty causes additional concerns for the health and safety of individuals with MoM hip 
implants that have failed and begun to degrade.
Once degradation of a MoM hip implant occurs, elevated levels of chromium and cobalt are 
seen in the bloodstream. In some instances, the increase can be up to ten times the levels 
seen in individuals without MoM implants.5 Inflammation, carcinogenic and teratogenic 
effects, and allergic reactions have been linked to the accumulation of these metals in the 
body.6 One step in gaining information about the effects of higher chromium and cobalt 
concentrations in the bloodstream resulting from failed MoM implants is determining the 
typical levels of these metals in the affected population. Biomonitoring data for these metals 
are needed for use as a baseline comparison. The reference values (Table 1) provided in the 
literature for these metals in whole blood are based on smaller scale studies, which typically 
target a small population for a short period of time within a narrow geographic area.4, 7-10 
As a result, the analytical results obtained are not reflective of typical values for the U.S. 
population as a whole. One avenue for gaining the required biomonitoring data is through 
the analysis of specimens collected in the National Health and Nutrition Examination Survey 
(NHANES). NHANES is used to assess the health and nutritional status of the United States 
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population. Biomonitoring data about environmental exposures to numerous chemicals are 
obtained through this survey and made publicly available in the year following the end of 
each two-year NHANES cycle. The MoM implant degradation issues prompted the 
incorporation of chromium and cobalt data collection into the 2015–2016 NHANES survey 
cycle. With this a baseline of the US population exposure values for cobalt and chromium 
are established through the analysis of NHANES specimens by our laboratory. Researchers 
can then begin to more accurately correlate certain adverse health effects with certain levels 
of exposure.
Before sample analysis collection could begin, our laboratory had to develop an analytical 
method that could accurately quantify these two metals in whole blood. CDC laboratories 
have previously developed and published work of human whole blood analysis by ICP-MS 
to measure other elements11-13. We used the method developed by Jones et al.13 in our 
laboratory for the selection of the sample preparation procedure. The sample preparation in 
alkaline dilutions is very straightforward and allows for direct sample analysis without any 
extra step like centrifugation. Previous methods of analyzing chromium in whole blood 
included the usage of atomic absorption spectrometry (AAS) or sector field inductively 
coupled plasma mass spectrometry (ICP-MS).14 However, both of these techniques have 
their limitations and drawbacks. AAS does not provide the detection limits needed to 
analyze these metals at the trace levels needed for biomonitoring purposes, and it does not 
allow for the measurement of multiple analytes simultaneously.10 When it comes to the 
detection of low level trace and toxic elemental analysis, ICP-MS is the method of choice 
given its sensitivity, multi-elemental analysis, high sample throughput and the ability to 
efficiently reduce and/or remove interferences by collision or reaction cells. Sector field 
ICP-MS is not a preferred technique to handle the sample throughput demands of a 
biomonitoring method because of the complexity and cost of the instrumentation.
The analysis of chromium and cobalt in blood matrices by quadrupole ICP-MS can be 
problematic due to polyatomic interferences. The interferences come from a number of 
different sources such as the sample matrix itself, the matrix of the reagents used for 
analysis, or the argon plasma15. Elimination or reduction of argon-based polyatomic 
interferences can take place in the collision cell by Kinetic Energy Discrimination (KED) 
using helium gas as the collision gas or in a reaction cell by reaction with a reactive gas like 
ammonia.16 These options are available for most commercial ICP-MS. The collision cell is 
pressurized with helium gas which collides with the ions. Such collisions will occur more 
frequently with larger polyatomic ions than smaller atomic analyte ions, hence, lowering the 
kinetic energy of the polyatomic ions relative to the atomic ions. The cell is maintained at a 
voltage more negative than the analyzing quadrupole creating the KED. The faster moving 
analyte ions are able to overcome it while the larger polyatomic ions are not. As a result, the 
analyte ions are separated from the interference ions.
In this paper, we discuss the biomonitoring method that we developed which uses 
quadrupole ICP-MS to rapidly and accurately quantify Co and Cr in human whole blood 
samples while eliminating the potential interferences that exist with the analysis of samples 
of this nature. The method is designed to support both small and large biomonitoring studies 
as well as epidemiological studies of possible exposures of public health significance. To 
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ensure the accuracy of the measurements reported, our laboratory also focuses on lot 
screening of the devices used in the sample collection, storage, and preparation processes to 
ensure that background levels of the analytes, particularly chromium, are not present in the 
items used for sample collection, storage, preparation or analysis of the samples for the 
NHANES program. We validated our method by looking at accuracy, precision, recovery, 
robustness, ruggedness, short-term stability and other parameters by using proficiency 
testing specimens obtained from the Centre de Toxicologie du Quebec (CTQ), historical 
proficiency specimens obtained for the New York Department of Health's (NYDOH) 
proficiency testing program, in-house quality control (QC) and Seronorm reference material.
Experimental
Reagents
We prepared all reagents using ≥18 MΩ·cm water from AQUA Solutions® water purification 
systems (Jasper, GA). Triton® X-100 (Sigma Aldrich, St. Louis, MO), 
tetramethylammonium hydroxide (TMAH, 25% in H2O, Alfa Aesar), ethanol (Pharmco 
Products Inc., Brookfield, CT), and ammonium pyrrolidine dithiocarbamate (APDC, Fisher 
Scientific) for the diluent/carrier and rinse solutions. We used ethanol, nitric acid (HNO3, 
environmental grade, GFS Chemicals, Columbus, OH) and double distilled hydrochloric 
acid (HCl, 30–35%, GFS Chemicals Inc.) to investigate potential interferences. We 
purchased “Base blood,” human whole blood with EDTA, for matrix matching of calibration 
curve from Tennessee Blood Services. We used single element stock standards from various 
sources (Inorganic Ventures, Christiansburg, VA, NIST Standards, Gaithersburg, MD, SPEX 
CertiPrep, Metuchen, NJ, and High-Purity Standards, Charleston, SC) for the preparation of 
intermediate calibration standards in 2% v/v HNO3 and 1% v/v HCl. All calibration 
standards are traceable to the National Institute for Standards and Technology (NIST, 
Gaithersburg, MD). Gallium (Ga) and scandium (Sc) are used as internal standards to allow 
for the correction of instrument noise and drift as well as sample-to-sample matrix 
differences. These elements were selected based on the fact that Sc and Ga are close to the 
mass range of the target analytes and that their concentration in whole blood is negligible or 
non-existent.4 We prepared the internal standard intermediate for the Ga and Sc mixture in 
1% v/v HNO3. Sample diluent and carrier solutions consisted of 20 μg/L Ga, 20 μg/L Sc, 
0.01% APDC, 0.4% (v/v) TMAH, 1% ethanol, and 0.05% Triton X-100. The rinse solution 
consisted of 0.01% APDC, 0.4% (v/v) TMAH, 1% ethanol, and 0.05% Triton X-100 as 
described previously.13
Calibrators and Sample Preparation
We prepared the Cr and Co spiked intermediate calibrations standards (S1-S8) with Cr and 
Co concentrations of 0.5, 1.5, 5.0, 7.5, 15, 45, 75, 100 μg/L in 2% HNO3/1%HCl using the 
1000 μg/mL stock analytical standards purchased from the vendor. From these solutions, two 
sets of matrix-matched working calibrators (S0-S5) and (S0, S5-S8) are prepared using a 
Hamilton Diluter by dispensing 0.25 mL of the intermediate standard, 0.25 mL of base 
blood, and 4.5 mL of diluent. Calibrator S0 is used as the blank for all working calibrators. 
A reagent blank is prepared using DI water instead of whole blood for patient samples, 
quality control and reference materials. We screened for Cr and Co the whole blood 
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purchased from Tennessee Blood Services before using it as base blood to make sure that it 
didn't contain Cr and Co. More specific information for the calibration curve can be found in 
the Calibration, Limits of Detection and Carryover section under Results and Discussion. 
The unknown blood specimens, in-house quality control (QC), and PT samples were 
prepared by mixing 0.250 mL of the unknown blood specimen, 0.250 mL of DI H2O, and 
4.5 mL of diluent. All prepared aliquots are a 20× dilution of blood.
Quality Control (QC) and Reference Materials
We used four levels of blood-based bench QC materials with the concentrations of two 
levels (named low and high) falling within the boundaries of the regular calibration curve 
and the concentrations of the other two levels falling within the boundaries of the extended 
calibration curve. The bench QC materials were analyzed at the beginning of each analytical 
run and again at the end. Our laboratory used modified Westgard rules as detailed in Caudill 
et al.17 to determine the acceptance or rejection of each analytical run from a quality control 
perspective. We established the bench quality control limits by characterization of data from 
52 analytical runs over a three month time span. We assessed method accuracy by preparing 
two samples that were spiked with NIST standard reference materials (SRM) 3112a 
(Chromium Standard Solution) and SRM 3113 (Cobalt Standard Solution) so that the 
resulting concentrations were 3 μg/L and 11 μg/L for Cr and Co, respectively. In addition, 
we used reference materials from the Québec Multielement External Quality Assessment 
Scheme (QMEQAS), Institut National de Santé Publique Québec, and Seronorm™ Trace 
Element Whole Blood (SERO AS, Norway) during method development and validation.
Instrumentation
We used a Thermo® iCAP™ Qa (upgraded to an iCAP Qc) ICP-MS with collision cell 
(QCell™) (Thermo Fisher Scientific) equipped with a peristaltic pump, a PFA-ST 
MicroFlow Nebulizer, a peltier-cooled cyclonic spray chamber, a 2.0 mm quartz injector, 
platinum sampler cone, platinum skimmer cone, and skimmer cone insert 3.5 mm for all 
experiments. The instrument parameters are listed in Table 2. We used a SC-4DQ FAST 
autosampler (Elemental Scientific Inc., Omaha, NE) for the uptake of diluted blood samples 
for analysis and to control the FAST sample introduction timing. See Table S1 in the 
supplemental information (SI) for detailed information on the FAST method. Our laboratory 
used > 99.999% argon (Specialty Gases Southeast, Atlanta, GA) for the plasma and 
nebulizer gases. We operated the collision cell in KED mode using helium (99.999% grade, 
Airgas South) gas. We analyzed base blood samples for 20 minutes prior to all experiments 
and sample analysis to stabilize the collision cell. We prepared final dilutions (i.e. working 
calibrators, QC, and unknown samples) for analysis using a Hamilton Microlab 625 
Advanced Dual Syringe Diluter (Hamilton Company, Reno, NV) equipped with a 10 mL 
dispensing syringe and a 500 μL sampling syringe.
Statistical Analyses
A mixed effect of the analysis of variance (ANOVA) was used to examine ruggedness. More 
specifically, the effect of small variations in these specific parameters: ethanol, KED gas 
flow, rinse time, TMAH, and sample dilution. We assumed that there were random effects 
from the vial (triplicates or quadruplicate from the same vial). Least square means from the 
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variations of the parameters were compared with the standard condition, and a p-value <0.05 
denoted a statistically significant difference.
We examined the short-term stability of Cr and Co in blood by analyzing QC materials at 
different conditions: room temperature, 48-hour test, refrigeration, and freeze-thaw cycles. 
Equal means under different conditions were tested using one-way mixed effect ANOVA 
models. We assumed that there were random effects from time or cycle (set as the category 
variable) and also from vial (duplicates or triplicates from the same vial). The scenarios with 
a p-value <0.05 had a statistically significant difference among the conditions that we tested. 
For the scenarios with a significant p-value, further statistical comparisons were performed.
Results and Discussion
Specificity
As previously mentioned, the analysis of Cr and Co in blood matrices by ICP-MS can be 
problematic due to polyatomic interferences. The interferences come from a number of 
different sources such as the sample matrix, the matrix of the reagents used for analysis, 
and/or the argon plasma.15 Since the interferences are the same mass as the analyte being 
measured, proper interference removal is necessary to ensure analytical specificity, meaning 
that only the analyte of interest is being quantified. To assess the specificity of chromium 
and cobalt in this method, we examined the potential interferences that could be present 
during ICP-MS analysis. To determine if the potential interferences were significant, we 
determined background equivalent concentrations (BEC) for Cr and Co during both standard 
mode (no interference removal used) and KED mode (used helium gas for interference 
removal) analysis by preparing spiked solutions with concentrations based on the maximum 
levels of the potential interference expected in human whole blood.4 The elimination or 
reduction of argon-based polyatomic interferences takes place in the collision cell by KED 
using helium gas as the collision gas. For Cr at m/z 52 in standard mode, significant levels of 
interference from chlorine (Cl), oxygen (O), hydrogen (H), nitrogen (N), argon (Ar), carbon 
(C), sulfur (S) and vanadium (V) in these 
species 35Cl16O1H+, 40Ar12C+, 37Cl15N+, 34S18O+, 36S16O+, 35Cl17O+,1H51V+ are 
expected.18 When our laboratory simulated the component concentrations of the blood 
matrix by spiking solutions with sulfur (500,000 μg/L), no interference was observed for Cr 
at m/z 52 from 34S18O+ or 36S16O+ polyatomic interferences. For the other interferences, we 
observed a level of interference in the standard mode. This was observed in the BEC values 
obtained from spiked solutions of Cl (1% HCl), calcium (Ca) (200,000 μg/L), and V (100 
μg/L). In the case of Co at mass-to-charge ratio (m/z) 59, interference from calcium, oxygen, 
hydrogen, magnesium (Mg), chlorine, nitrogen, scandium (Sc), nickel (Ni), argon and 
sodium (Na) in these 
species 43Ca16O+, 42Ca16O1H+, 24Mg35Cl+, 14N45Sc+, 1H58Ni+, 36Ar23Na+, and/
or 40Ar18O1H+ is expected.18 No interferences were observed from 24Mg35Cl+, 14N45Sc+, 
or 1H58Ni+ when solutions were spiked with Mg (50,000 μg/L), Cl (1% HCl), Sc (100 μg/L) 
and Ni (100 μg/L). The BEC obtained for Ca and Na in standard mode showed some degree 
of interference. Overall, for some of the elements, BEC values were obtained in the standard 
mode; therefore, KED mode using helium at a flow rate of 5.0 mL/min was used for the 
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removal of these interferences. Initially, the helium gas flow rate used during the KED mode 
was optimized by the ICP-MS software for 51ClO interference. In addition it was observed 
in the literature that the He gas for the collision cell fell between 4.0-5.0 mL/min9, 14, 19, 20. 
After the instrument optimization, the He gas flow rate was further evaluated for Cr and Co 
by looking at their intensities while in matrix solutions at flow rates between 4.0-6.0 mL/
min. It was determined that 5.0 mL/min was the best flow rate for the removal of the 
interferences. The data in table 3 substantiates the idea that the use of the collision cell 
significantly reduces the level of interferences present in human blood coming from Cl, S, V, 
and Ca for Cr at m/z 52 and from Ca and Na for Co at m/z 59. These results show that KED 
mode is necessary for ICP-MS analysis of Cr and Co in blood with this analytical method.
Calibration, Limits of Detection and Carryover
After optimization of the operating parameters, our laboratory determined the analytical 
response characteristics for chromium and cobalt. We used the reference ranges in Table 1 to 
determine the analyte concentrations to be covered by our method during the method 
development process. For this reason, we determined that two separate calibration curves 
would be used for sample analysis. The regular calibration (0.5, 1.5, 5.0, 7.5, 15 μg/L) 
covers analyte concentrations up to 15 μg/L. We anticipated that the majority of the samples 
analyzed would most likely fall below 15 μg/L based on the reference ranges found in the 
literature (Table 1). The extended calibration (15, 45, 75, 100 μg/L) covers samples with 
analyte concentrations above our normal threshold of 15 μg/L but below 100 μg/L. With 
both calibration ranges, linear responses and ≥ 0.9950 coefficients of correlation (R2 values) 
were obtained for Cr and Co response function.
Limit of detection (LOD) determinations were based on the analysis of four concentration 
levels (matrix blank and first three calibrators) from 60 analytical runs over three months. 
For this method, the matrix blank was used to satisfy the criterion of having a level below 
the LOD while the first three calibrators of the standard calibration curve were used for the 
other three levels. The method used to calculate the LODs is based on the recommendations 
of the Clinical and Laboratory Standards Institute (CLSI)21 and take both Type I and Type II 
errors into consideration. For linear relationships the following equation is used to calculate 
the LOD: concLOD = [meanb + 1.645*(Sb + B)] / (1-1.645*A) where meanb is the mean of 
the blank, Sb is the standard deviation of the blank, B is the y-intercept, and A is the slope. 
For quadratic relationships (y=Ax2 + Bx+C), the following equation is used to calculate the 
LOD: concLOD = [-b ± sqrt (b2 -4ac)] / 2a where a=1.645*A, b= (1.645*B)-1, and c= meanb 
+ 1.645*(Sb+C). With both linear and quadratic relationships, the resulting calculated LOD 
has a 5% false negative rate. A linear relationship was the best fit with this analytical 
method, and the limits of detection for chromium and cobalt in whole blood were 
determined to be 0.41 μg/L and 0.06 μg/L, respectively.
We evaluated analyte carryover multiple days by alternating the analysis of blood samples 
(the highest calibrator in extended curve) containing approximately 100 μg/L of each analyte 
and aqueous blanks over the period of ∼3.5 hours (analysis time of 2 minutes per sample 
with 98 samples analyzed). The intensities and resulting concentrations of both analytes in 
the 100 μg/L sample were stable over the full 3.5 hour run. (Figure S1a-b). The data for the 
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aqueous blanks showed a spike in Co and Cr intensities at sample 33 bringing the calculated 
Co concentration of that sample to 0.74 μg/L which was above the cobalt limit of detection 
(LOD) of 0.06 μg/L. The Cr concentration remained below LOD of 0.41 μg/L (Figure S1c-
d). Our laboratory decided to limit the number of patient samples in an analytical run to 30 
samples, thereby ending the analytical run before the point where an intensity spike would 
potentially be observed. For the next run a new calibration curve and QC material needs to 
be prepared.
Precision, Accuracy, and Recovery
To ensure the method's short-term and long-term reproducibility, we evaluated CTQ 
proficiency samples and in-house CDC quality control (QC) samples. The short term 
precision was evaluated by analyzing 19 CTQ proficiency testing samples in one analytical 
run. All of the results for chromium and cobalt were within the allowable ranges established 
by the PT program as summarized in Table 4. Several samples had recoveries slightly 
outside of the 90–110% range; however, average recoveries for chromium and cobalt were 
99 ± 9% and 101 ± 12%, respectively. We determined the analyte concentrations in the in-
house QC samples by characterizing “low” and “high” blood quality control pools spiked 
with these analytes. Table 5 summarizes the calculated results for the QC samples over 50 
analytical runs for low and high QC samples and over 30 runs for both elevated QC levels. 
For chromium and cobalt, the among-run precision for the low (Co 1.66 μg/L and Cr 2.58 
μg/L) and high (Co 8.89 μg/L and Cr 12.3 μg/L) QC are <13% and <7% relative standard 
deviation (RSD), respectively, over 52 analytical runs over a time period of 2 months.
Our laboratory evaluated accuracy and recovery by analyzing aliquots from two pools of 
human whole blood materials which were previously spiked with known amounts of 
chromium and cobalt. We spiked one pool so that the resulting concentration of each analyte 
was 3 μg/L and the other pool to have a resulting concentration of 11 μg/L for each analyte. 
NIST SRM 3112a (Chromium Standard Solution) and SRM 3113 (Cobalt Standard 
Solution) were used for the spiking. The samples were analyzed with different sets of 
calibrators (different lots from different vendors). Bench QC material, CTQ samples, and 
New York Department of Health (NYDOH) proficiency samples were also evaluated in 
terms of accuracy and recovery.
We generated correlation and bias plots containing acceptable results from the analysis of 
the various types of samples (NYDOH, CTQ and Seronorm) used them to evaluate accuracy 
and recovery for Cr and Co (Figure S2a-d). A slight, positive concentration bias was seen 
with cobalt, particularly with concentrations above 2 μg/L. With NYDOH proficiency testing 
materials, the positive bias was more pronounced in comparison to the bias in CTQ and 
Seronorm materials (Table S2-S3). The percent bias (% bias) seen with the NYDOH 
samples for Co range between 0 – 29 % bias and for Cr between 0 – 46 % bias (with the 
exception of an outlier sample at 100% bias). The correlation bias was also more 
pronounced with the Seronorm material than the CTQ material. A contributing factor to this 
bias is that unlike the CTQ samples which are made from human whole blood, the NYDOH 
materials are made from caprine (goat) blood and the Seronorm is made from lyophilized 
blood. NYDOH and CTQ results are based on the robust average obtained by employing 
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algorithms described in ISO 13528:2005 guidelines from the results reported by all 
participating laboratories in the event. In our study, we use human whole blood for all of our 
analyses, but other laboratories most likely use caprine blood to make calibration and QC 
materials because of the difficulty in obtaining human blood. With all of the materials 
analyzed, our results were within the acceptability ranges specified by the vendors. A 
summary of the chromium and cobalt results for the spike solutions, QC samples, CTQ 
samples, PT samples, and reference materials is provided in Tables 6 and 7.
Ruggedness
We tested the capacity of our method to remain unaffected by small variations in specific 
parameters. Meaning, we wanted to determine how much the accuracy varies with changes 
to five method parameters likely to affect accuracy. This assessment is part of our method 
validation as stated in the CDC Division of Laboratory Sciences Policies and Procedures 
Manual. We tested five parameters through the analysis of high bench QC samples: the 
sample rinse time, the percentage of TMAH and ethanol in the diluent, and the KED gas 
flow rate. Tables S4–S8 show the analytical results obtained for the high bench QC that was 
analyzed during the assessments of the different parameters and the results for the statistical 
evaluations performed on this data. A mixed effect of ANOVA was used to check for a 
statistically significant difference between the two settings (standard value and lower or 
higher parameters). A p-value less than 0.05 indicates that there is a statistically significant 
difference between the two settings. Table 8 shows the p-values for the parameters 
examined.
With our analytical method, the dilution factor used for sample preparation is 20×. We 
evaluated dilution factors of 15× (25% lower than the typical dilution factor) and 25× (25% 
higher than the typical dilution). For both analytes, statistical evaluation of the results 
showed a statistical significance (p < 0.05) between samples prepared with the normal 
dilution factor and samples prepared with the smaller / higher dilution factors. When 
comparing the results obtained to the characterized QC results (target mean and ±2SD 
range), we found that the results using 15× and 25× dilutions were not within our QC 
acceptance limits; therefore, the statistical significance seen is valid. We concluded that the 
method does not provide acceptable results at dilution factors outside of the established level 
for this method.
The autosampler rinse time used in our established method is 33 seconds. Rinse times of 24 
seconds (approximately 27% lower than the typical rinse time) and 39 seconds 
(approximately 18% higher than the typical rinse time) were evaluated. For both analytes, 
statistical evaluation of the results showed a statistical significance (p < 0.05) between the 
normal rinse time and the shorter rinse time. When comparing the least squares means to the 
characterized QC results (target mean and 2SD range), we found that the results using a 24-
second rinse time were well within our QC acceptance limits. The presence of a statistical 
significance does not translate into scientific significance in this case. A statistically 
significant difference was not found between the normal rinse time and the longer rinse time. 
We concluded that our method is robust enough to withstand fluctuations in the rinse time.
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The percentage of TMAH in the diluent in the established method is 0.4%. We evaluated 
diluent TMAH percentages of 0.3% (25% lower than the typical TMAH percentage in the 
diluent) and 0.5% (25% higher than the typical TMAH percentage in the diluent). For both 
analytes, statistical evaluation of the results showed statistical significance (p < 0.05) 
between the normal and lower diluent TMAH percentages for Cr, the normal and lower 
TMAH percentages for Co, and the normal and higher TMAH percentages for Co. When 
comparing the least squares means to the characterized QC results (target mean and 2SD 
range), we found that the analytical results were well within our QC acceptance limits. In 
this test, the presence of a statistical significance does not translate into scientific 
significance. A statistically significant difference was not found between the results from the 
diluents with normal and higher TMAH percentages for Cr. We concluded that our method 
is robust enough to withstand fluctuations in the percentage of TMAH in the diluent.
Further, the percentage of ethanol in the diluent in the established method is 1%. We 
evaluated diluent ethanol percentages of 0.8% (20% lower than the typical ethanol 
percentage in the diluent) and 1.2% (20% higher than the typical ethanol percentage in the 
diluent). For both analytes, statistical evaluation of the results showed a statistical 
significance (p < 0.05) between the normal and increased ethanol amounts for Cr and Co. 
When comparing the least squares means to the characterized QC results (target mean and 
2SD range), we found that the results were well within our characterized QC acceptance 
limits for both analytes. In this test, the presence of a statistical significance does not 
translate into scientific significance. A statistically significant difference was not found 
between results from the diluents with normal and lower ethanol percentages for either 
analyte. We concluded that the method is robust enough to withstand fluctuations in the 
percentage of ethanol in the diluent.
The KED gas flow used in the established method is 5 mL/minute (min). Our laboratory 
evaluated gas flows of 4 mL/min (20% lower than the typical gas flow) and 6 mL/min (20% 
higher than the typical gas flow). For both analytes, statistical evaluation of the results 
showed statistical significance (p < 0.05) between the normal gas flow rate and the higher 
gas flow rate. There was also a statistically significant difference between the normal gas 
flow rate and the lower gas flow rate for Cr but not Co. It is important to note the statistical 
significance does not necessary signify scientific importance. Since chromium least squares 
means of13.02, 12.25, and 12.08 μg/L for 4, 5, and 6 mL/min gas flow, respectively and 
cobalt least square means of 8.99 and 9.11 μg/L for 5 and 6 mL/min, respectively are well 
within our QC acceptance limits (Cr - 12.26 ± 1.2 μg/L and Co - 8.89 ± 0.94 μg/L, mean 
± 2SD), we conclude that there is no definitive evidence that one flow rate is better than 
another in range of 4-6 mL/min. However, we chose 5 mL/min KED gas flow as the 
optimum condition for this parameter since Cr and Co concentrations came the closest to the 
QC target mean (which also correlates the closest with the actual amount of Cr and Co 
spiked into the QC pool). Additionally, it was determined that 5.0 mL/min was the best flow 
rate for the removal of the interferences (specificity section).
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Robustness
The degree of reproducibility obtained under a variety of conditions within the laboratory 
were assessed using the Pearson Correlation Coefficient, r. The method was evaluated by 
analyzing the same set of proficiency testing samples by different analysts, on different 
instruments, with different reagents (different calibrator lots), and on different days. The r 
for each analyte under each condition was calculated to be greater than 0.99 (values larger 
than 0.95 signify there is no difference between two variables), Table 9, meaning no 
statistically significant differences were found in Cr and Co concentrations from two 
different analysts, instruments, calibrators, and analysis time. We conclude that the 
developed method passes robustness testing and is stable.
Linearity
To evaluate the linearity of this method, we analyzed spiked blood samples with 
concentrations outside of the regular and extended calibration ranges. We analyzed three 
base blood samples spiked with 20, 50, and 100 μg/L of each analyte using the regular 
calibration curve. These samples were analyzed in triplicate on two different days with three 
different calibration lots. Average measured concentrations and recoveries are listed in Table 
S9. Figures 1 (a) and (b) display two linear curves. Curve (a) is a plot of the five regular 
calibration standards versus their relative ion signal (analyte of interest's intensity divided by 
the internal standard intensity), plus three spiked samples (20, 50, and 100 μ/L). When 
examining the two calibration lines, we can assess how linear the calibration is beyond the 
highest calibration point of 15 μg/L. For both analytes, the two curves have identical slopes 
and very close correlation coefficients (R2) values which led us to conclude that the linearity 
continues beyond the top of the regular calibration range (15 μg/L up to 100 μg/L). It is 
important to note that average percent recoveries for Co at 20 and 100 μg/L were higher than 
110%, Table S9.
To test the linearity of the method beyond the extended calibration range, we analyzed ten 
spiked base blood samples with concentrations in the range of 150 to 5000 μg/L (Table S10). 
We analyzed the samples in triplicate on two different days with two calibration lots with the 
exception of the 150 and 750 μg/L samples which were analyzed in triplicate with one 
calibration lot. Figures 1 (c) and (d) display two linear curves plus ten elevated samples (see 
concentrations in Table S10). For both analytes, the two curves (a) and (b) have identical 
slopes and R2 values of approximately one. This led us to conclude that the linearity 
continued beyond the extended calibration range. However, average percent recoveries are 
higher than 110% for Co over 500 μg/L and for Cr over 1500 μg/L. Additionally the detector 
switches to the analog mode (higher than 1.5 million counts per second) at these two 
concentrations. Traditionally, we like to avoid analyzing samples in analog mode if 
calibration curves are analyzed in pulse detector mode22. Per the standard procedures of this 
method, samples above 100 μg/L would be diluted, and patient results would be reported 
from the dilution.
Range
The majority of the patient samples that our laboratory would receive for analysis would 
have concentrations towards the lower end of our calibration range 4, 7-10. To determine how 
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to treat samples with concentrations above 15 μg/L, we looked at two different concentration 
ranges: samples between 15 μg/L and 100 μg/L and samples above 100 μg/L. The first range 
is representative of patient samples with MoM implants, and the second range is for extreme 
cases with dangerous degradation of the MoM hip implants or total failure of the 
implants7, 9, 23-30.
For samples between 15 μg/L and 100 μg/L, we tested the possibility of diluting elevated 
samples with base blood in order to bring them within our established calibration range. Two 
spiked samples were diluted with base blood: a 25 μg/L sample was diluted 2× and 5×, and a 
100 μg/L sample was diluted 10× and 20× (Table S11). Samples were prepared on two 
different days with three different sets of calibration materials. The average recovery for 100 
μg/L samples diluted 10× was approximately 120% for both Cr and Co; therefore, we 
decided to use an extended calibration curve instead of dilution for samples with 
concentrations between 15 μg/L and 100 μg/L.
To cover extreme cases where the concentration of one or both analytes can approach or 
extend into the parts per million range, we explored the analysis of samples with 
concentrations above 100 μg/L by evaluating dilution of specimens that fall into that 
category. Dilution was done with deionized (DI) water. We tested a number of sample 
concentrations and dilution factors were tested to determine the maximum concentration and 
dilution factor that could be used for this analytical method. The results are shown in Table 
S12 show that the average recovery for Cr up to 6000 μg/L (100× dilution) was acceptable 
(within 10% of the target). Co showed acceptable results up to 20,000 μg/L (200×) dilution. 
However, when this study was repeated, the results were inconsistent.
To investigate this further, we spiked seven elevated samples with standards used to make 
working calibrators and diluted them with base blood instead of DI water (Table S13). The 
samples were analyzed in triplicate with three different calibration curves on three different 
days. For samples with Cr and Co concentrations of 5500 μg/L, a 100× dilution gave 
recoveries that exceeded 110%. We subsequently spiked two samples (3000 and 5000 μg/L) 
with standards used to make the working calibrators and diluted these samples 50× with 
base blood (Table S14). These samples were analyzed in triplicate with four different 
calibration curves over two days. The recoveries were 102% and 99% for Cr and 100% and 
97% for Co, respectively. Examining the data in its entirety, we set our clinically reportable 
range to 5000 μg/L. A 50× dilution is the maximum dilution that can be performed using 
base blood and an extended calibration curve.
Analyte Short-Term Stability
We examined the short-term stability of Cr and Co in blood by analyzing QC material at 
different storage conditions. First, we tested the stability of Cr and Co in undiluted low 
bench QC at room temperature for 64 hours. Next, we tested analyte stability by prolonging 
the time between sample preparation and sample analysis. The maximum anticipated delay 
time before analysis was 48 hours. We evaluated a number of time points at two different 
temperatures – ambient temperature and 4°C. The stability of the analytes in the matrix was 
also evaluated for two freeze-thaw cycles. The least squares means under different 
conditions were tested using one-way mixed effect ANOVA models (Table 10). We made the 
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following assumptions: there are random effects resulting from time or cycle (set as the 
category variable) and random effects resulting from vial-to-vial variation or variation 
among replicates from the same vials. P-values of < 0.05 indicated a statistically significant 
difference among the conditions being compared. For scenarios with a significant p-value, 
further statistical comparisons were performed.
Room Temperature
We stored fifteen undiluted low bench QC samples at room temperature. At three different 
time points (24, 48 and 64 hrs.), we used five vials to make preparation samples for analysis 
in triplicate (15 samples to be analyzed at each time point). This experiment covered a 64-
hour time period. For Cr, a statistically significant difference was not seen amongst the 
results (p=0.7958), Table 10. However, with Co, a p-value of <0.0001 (Table 10) indicated a 
statistically significant difference amongst the results at the different time points. As a 
further comparison, we compared the results at 48 hours with the results at 24 hours and the 
results at 64 hours with the results at 24 hours. Both revealed a statistically significant 
difference. When we compared the cobalt results obtained in this stability study to the 
characterized QC limits, although the majority of the Co results were above the 
characterized mean, none of the results were outside of +2SD of our characterized mean. 
Only one third of the results were outside of +1SD. We concluded that while a statistically 
significant difference did not exist in Cr results across time, a statistically significant 
difference existed for cobalt. The statistical significance seen with the cobalt results did not 
have scientific relevance because our recoveries were still within our statistical limits 
(±2SD) for our QC materials.
48-Hour Test
We diluted twenty-one low bench QC samples in triplicate. We stored the 63 diluted samples 
at room temperature and analyzed nine samples for each of the different time points over the 
48-hour testing period. For both analytes, a statistically significant difference was not seen 
amongst the results; therefore, we concluded that leaving the digested samples at room 
temperature for up to two days has no effect on the recovery of the analytes.
Refrigeration
We diluted fifteen low bench QC samples in triplicate. We refrigerated the resulting 45 
prepared samples at 4°C. We analyzed groups of 15 samples at each of the three time points 
over a 48-hour period. For both analytes, a statistically significant difference was seen 
amongst the results at the different time points. As a further comparison, we statistically 
compared the results at 24 hours with the results at 4 hours and the results at 48 hours with 
the results at 4 hours. In the case of Cr, a statistically significant difference was seen 
between the results at 24 hours and the results at 4 hours. With Co, a statistically significant 
difference was seen between the results at 48 hours and the results at 4 hours. With both 
analytes, the results were compared to the characterized QC data for this QC pool, and the 
results were within our laboratory's QC statistical limits of acceptability (±2SD); therefore, 
the statistical significance seen does not translate into scientific relevance. It was concluded 
that diluted samples can remain in the refrigerator for up to two days prior to analysis 
without adversely affecting the recovery of the analytes.
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Freeze-thaw Cycles
We removed ten low bench QC samples from the freezer, thawed them, prepared aliquots 
taken from the vials in duplicate, and returned the unused portions of the original 10 samples 
to the freezer. We analyzed the diluted samples. The following day, we removed the same 
ten original from the freezer, thawed them, and prepared aliquots taken from the vials in 
duplicate. We analyzed the diluted samples and statistically compared the results from both 
days. For Cr, a statistically significant difference was not seen amongst the results 
(p=0.7122). However, with Co, a p-value of <0.0001 indicated a statistically significant 
difference amongst the results from the two days. To further evaluate cobalt, we compared 
day one results against day two results, and a p-value of <0.0001 was obtained again. We 
compared the individual results from both days to the characterized QC mean for Co of 1.66 
μg/L, and the results from this experiment ranged from 1.60 μg/L to 1.72 μg/L. All results 
were within one standard deviation of the mean; therefore, although a statistical significance 
is present, the difference has no scientific relevance.
Conclusion
We successfully developed a biomonitoring method to accurately and rapidly quantify Cr 
and Co in human whole blood by ICP-MS operated in KED mode. Because there is no 
whole blood reference material with certified target values for Cr and Co, the commercially 
available reference material lyophilized blood Seronorm Trace Elements Whole Blood, 
proficiency testing samples, and in-house QC were employed and characterized during the 
day-to-day method validation analysis. We determined that an analytical run will include 30 
patient samples in addition to the blanks, calibrators, and quality control materials. We 
conducted experiments to determine ruggedness by quantitatively altering method 
parameters to determine if the variations affected the analytical results obtained. We 
concluded that only changes in the dilution factor during sample preparation had a 
significant impact on the results because these changes produced resulting QC 
concentrations outside of our QC acceptance ranges for both analytes. The same set of 
proficiency testing samples by different analysts, on different instruments, with different 
reagents, and on different days showed that the method is rugged. Statistical analysis, such 
as fixed effects linear model, step-down pairwise comparison, and equivalence test 
confirmed the short-term stability of Cr and Co in human whole blood.
This analytical method is used to support the acquisition of U.S. population data for 
chromium and cobalt in whole blood by analyzing specimens collected during the 2015–
2016 National Health and Nutrition Examination Survey (NHANES) cycle. For chromium 
and cobalt in blood, NHANES targets exposure for the demographic group comprised of 
individuals over 40 years old which is the group most likely to have had a MoM implant. 
When this data is evaluated and made publicly available at the end of the cycle, researchers 
will be able to compare exposure data for the baseline population with data from individuals 
who have had an implant to determine if people with the implant have elevated levels of Co 
or Cr. Hence, researchers can then begin to more accurately correlate certain adverse health 
effects with certain levels of exposure to these two metals.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(a) Regular calibration curve and linearity range for Cr, (b) regular calibration curve and 
linearity range for Co, (c) extended calibration curve and linearity range for Cr, (d) extended 
calibration curve and linearity range for Co.
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Table 1
Reference Ranges for Chromium and Cobalt4, 7-10
Analyte Information Reference Ranges μg L-1
Cr Healthy adults in fasting state 0.7 to 28.0
Co
(N=64) 9 with no implants 0.224 to 0.565
National Institute for Research and Safety 0.8
(N=130) Germany 0.04-8
French study healthy individuals (N=100) 0.04 – 0.64
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Table 2
Instrument Parameters for the Thermo ICAP-Qc
Plasma Power 1550 W
Cool Flow (Ar) 14 L min-1
Auxiliary Flow (Ar) 0.8 L min-1
Nebulizer Flow (Ar) ∼ 0.95 L min-1
KED Mode Gas Flow (He) 5 mL min-1
Method Parameters
Sweeps/Reading 20
Survey Run 1
Replicates 3
Dwell Times 200 ms for 
52Cr and 53Cr, 250 ms for 50Co
100 ms for 71Ga and 45Sc
Scan Mode Peak Hopping
KED Mode Gas Flow (He) 5 mL min-1
Peristaltic Pump 40 rpm
Sample Loop 2.0 mL
Sample Flush Time 4 s
Read Delay Time 15 s
Wash Time 30 s
Internal Standard 71Ga and 45Sc (20 μg L-1)
Calibration Type External Simple LinearMatrix Matched
Calibration (μg L-1) 0.0, 0.5, 1.5, 5.0, 7.5, 15.0
Sample Preparation 20× dilution
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Table 3
Potential interferences and Background Equivalent Concentration (BEC) for Cr and Co 
in ICP-MS.15
BEC (μg L-1)
Potential interferences Concentration Tested (μg L-1)* Standard mode KED Mode
Cobalt (59Co)
43Ca16O+, 42Ca16O1H+ 200,000 0.43 0.07
24Mg35Cl+ 50,000 for Mg / 1% HCl for Cl 0/0 0/0
36Ar23Na+ 500,000 0.01 0
14N45Sc+ 5/100 0 0
1H58Ni+ 100 0 0
40Ar18O1H+, 40Ar19F+, 36Ar23Na+, ICP gas - -
Chromium (52Cr)
35Cl16O1H+, 37Cl15N+, 35Cl17O+ 1% HCl 1.9 0.02
40Ar12C+, 36Ar16O+, 38Ar14N+, 36Ar15N1H+ ICP gas - -
34S18O+, 36S16O+ 500,000 0 0
1H51V+ 100 0.50 0
40Ca12C 200,000 0.16 0.6
*Concentration based on maximum levels expected in human whole blood.4
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Table 9
The Pearson Correlation Coefficient for Cr and Co for four analytical comparison 
parameters
Pearson Coefficient
r
Comparison Chromium Cobalt
Different analysts 0.995 0.999
Different instruments 0.992 0.999
Different reagents 0.996 0.998
Different days 0.991 0.998
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Table 10
Statistical evaluation results of assessing the stability of spiked samples at different 
conditions
Scenario p-value Comparison
Chromium
48 hours 0.3700
Room Temperature 0.7958
Refrigerated 0.0004 24 hr vs 4 hr: p-value =0.0001; 48 hr vs 4 hr: p-value =0.1793
Freeze-thaw cycles 0.7122
Cobalt
48 hours 0.8764
Room Temperature <0.0001 48 hr vs 24 hr: p-value =0.0019; 64 hr vs 24 hr: p-value <0.0001
Refrigerated 0.0033 24 hr vs 4 hr: p-value =0.0578; 48 hr vs 4 hr: p-value =0.0428
Freeze-thaw cycles <0.0001 Cycle 2 vs cycle 1: p-value <0.0001
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